Aakash Desai Highlighted JTO Study on MTAP as Biomarker in NSCLC
Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn:
“A new study in the International Association for the Study of Lung Cancer Journal of Thoracic Oncology highlights a crucial diagnostic detail for non-small cell lung cancer (NSCLC).
Researchers found that using immunohistochemistry (IHC) to directly assess MTAP protein deficiency is more reliable than using CDKN2A gene loss as a surrogate marker. The study revealed that CDKN2A loss, often checked in sequencing panels, can overestimate actual MTAP loss in over 25% of cases.
Why it matters:
Since MTAP status is a potential biomarker for response to PRMT5 inhibitors and immune-checkpoint inhibitors, accurately identifying it is critical for patient stratification and treatment selection.”
Title: MTAP expression by immunohistochemistry: a novel biomarker in non-small cell cancer of the lung
Journal: JTO
Authors: Magdalena M Brune, Luca Roma, Obinna Chijioke, Ilaria Alborelli, Martin Zacharias, Lenard Bubendorf, Tatjana Vlainic, Nikolaus Deigendesch, Julian Pollinger, Petra Hirschmann, David König, Sebastian Ott, Spasenija Savic-Prince, Lukas Bubendorf
More posts featuring Aakash Desai on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023